Regeneron   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tarrytown NY United States (1988)

Organization Overview

First Clinical Trial
2001
NCT00036946
First Marketed Drug
2008
rilonacept (arcalyst)
First NDA Approval
2008
rilonacept (arcalyst)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Regeneron Pharmaceutical | Regeneron Pharmaceuticals | REGENERON PHARMACEUTICALS